The factors that organize the internal membranes of cells are still poorly understood. We have been addressing this question using striated muscle cells, which have regular arrays of membranes that associate with the contractile apparatus in stereotypic patterns. Here we examine links between contractile structures and the sarcoplasmic reticulum (SR) established by small ankyrin 1 (sAnk1), a ~17.5kDa integral protein of network SR. We used yeast-two-hybrid to identify obscurin, a giant, Rho-GEF protein, as the major cytoplasmic ligand for sAnk1. The binding of obscurin to the cytoplasmic sequence of sAnk1 is mediated by a sequence of obscurin that is C-terminal to its last Ig-like domain. Binding was confirmed in two in vitro assays. In one, GST-obscurin, bound to glutathione-matrix, specifically adsorbed native sAnk1 from muscle homogenates. In the second, MBP-obscurin bound recombinant GST-sAnk1 in nitrocellulose blots. Kinetic studies using surface plasmon resonance yielded a K D =130nM. Upon subcellular fractionation, obscurin was concentrated in the myofibrillar fraction, consistent with its identification as sarcomeric protein. Nevertheless, obscurin, like sAnk1, concentrated around Zdisks and M-lines of striated muscle. Our findings suggest that obscurin binds sAnk1, and are the first to document a specific and direct interaction between proteins of the sarcomere and the SR.
INTRODUCTION
The mechanisms that organize the internal membrane systems in eukaryotic cells are poorly understood. We are studying this question in striated muscle, which has two highly organized internal membranes, the transverse (t-) tubules and the sarcoplasmic reticulum (SR) (Franzini-Armstrong, 1994; Flucher and Franzini-Armstrong, 1996; Leong and MacLennan, 1998 ).
The SR of striated muscle is an intricate web of intracellular membranes that, with the sarcolemma and t-tubules, modulate cytosolic Ca ++ during contraction and relaxation (FranziniArmstrong and Peachey 1981; Flucher, 1992; Franzini-Armstrong, 1999) . The SR closely surrounds and interacts with the myofibrils, but the molecules that organize and stabilize these connections are not known. We recently characterized a small form of ankyrin in the SR that may play an important role in these processes (Zhou et al., 1997) .
Ankyrins are multifunctional adaptor proteins of the plasma membrane and intracellular membranes (Bennett and Chen, 2001) . They contribute to the formation and cytoskeletal anchoring of specialized membrane domains. They also participate in signal transduction and protein sorting through their binding to ion pumps, Ca ++ release channels and cell adhesion molecules (De Matteis and Morrow, 1998; Rubstov and Lopina, 2000) .
Mammals have three distinct ankyrin genes, ANK1, ANK2 and ANK3, that produce a variety of tissue-specific and developmentally regulated products (Sedgwick and Smerdon, 1999; Bennett and Chen, 2001) . Canonical ankyrins, encoded by all three genes, have molecular masses of ~190-210 kDa and share three highly conserved structural domains: an NH 2 -terminal, ~89 kDa membrane binding domain, a central ~62 kDa spectrin binding region, and a ~55 kDa COOH-terminal domain (Mohler et al., 2002) . However, giant proteins encoded by ANK2 and ANK3 that carry additional structural motifs (Otto, et al., 1991; Kordeli and Bennett, 1991; Kunimoto, 1995; Zhang and Bennett, 1998) , and smaller forms encoded by ANK1 and ANK3 that lack domains of the canonical ankyrins (Peters, et al., 1995; Devarajan et al., 1996; Hoock et al., 1997; Zhou et al., 1997; Birkenmeier et al., 1998; Gallagher et al., 1998) , have also been identified.
Ankyrin 2 (or ankyrin B) is mainly expressed in brain and cardiac muscle (Otto et al., 1991; Tuvia et al., 1999) , whereas ankyrin 3 (or ankyrin G) products are present in epithelial cells, the nervous system, striated muscle and intracellular organelles including the Golgi apparatus and lysosomes (Kordeli et al., 1994; Peters et al., 1995; Devarajan et al., 1996; Hoock et al., 1997; Gagelin et al., 2002) . Isoforms of ankyrin 1 (or ankyrin R) are present in red blood cells, neurons and striated muscle (Lambert et al., 1990; Lux et al., 1990; White et al., 1992; Birkenmeier et al., 1993) .
The ANK1 products in striated muscle include large, canonical (~210 kDa) and small (~17-19 kDa) ankyrins (Gallagher et al., 1997; Zhou et al., 1997; Birkenmeier et al., 1998) . The large ankyrin isoform is concentrated at the sarcolemma of skeletal myofibers, whereas sAnk1 is targeted to the SR, and specifically to the network SR, which is primarily responsible for Ca ++ uptake. Consistent with its location, sAnk1 is present in a reticulum around the Z-disks and Mlines of the contractile apparatus. sAnk1 lacks both membrane and spectrin binding sequences and retains only a short sequence from the COOH-terminus of large ankyrin 1. The NH 2 -5 terminal portion of sAnk1 contains an unique 73-amino acid segment, the first 29 residues of which are hydrophobic and anchor the protein to the SR membrane. The remaining 126 amino acids of sAnk1 face the myoplasm (our unpublished studies). In short, sAnk1 seems to be organized in the network SR to enable it to interact with myofibrillar proteins.
We tested this idea by identifying potential binding partners of sAnk1. Using the yeast two-hybrid screen, we show that obscurin (Young et al., 2001 ), a giant (~800 kDa), sarcomeric protein, is a major cytoplasmic ligand for sAnk1. The binding to sAnk1 is mediated by the region of obscurin immediately following its last Ig-like domain. We use in vitro assays, kinetic analysis by surface plasmon resonance, and immunofluorescence techniques to demonstrate that this binding is specific, direct and likely to be physiological.
MATERIALS AND METHODS

Yeast two-hybrid screening and β-galactosidase assay
The Matchmaker LexA two-hybrid system was used as prescribed by the manufacturer (Clontech, Palo Alto, CA). A fragment encoding the COOH-terminal tail of sAnk1 aa29-155 (Birkenmeier et al., 1998) For domain mapping, deletion constructs of the COOH-terminal sequence of sAnk1 and obscurin clone F were generated by PCR amplification and introduced into the EcoRI/XhoI sites of the pLexA bait and pB42AD prey vectors, respectively. The following sets of primers were used for amplification of the sAnk1 deletion constructs; for sAnk1-A, the sense primer (i) was used in combination with the anti-sense primer (iii): 5' ACTGCTCGAGTTGTTCCTCTGTCAC 3', for generation of sAnk1-B the sense primer (iv): 5' ACTGGAATTCTTCACAGACGAACAG 3' was used along with the anti-sense primer (ii) and for sAnk1-C, the sense primer (v): 5' ACTGGAATCATCTCCACCAGGGTG 3' was used in conjunction with the anti-sense primer (vi): 5' ACTGCTCGAGTCCACTCCCTCTTAG 3'. GST and GST-obscurin clone F proteins were bound to glutathione-Sepharose and mixed with 0.5 mg of quadriceps muscle homogenate at 4 0 C for 16 h. Beads were washed in the cold with 10 mM NaPO 4 , pH 7.2, 120 mM NaCl, 10 mM NaN 3 , 0.1% Tween-20, and heated for 5 min at 90 0 C in 2xSDS Laemmli sample buffer. The soluble fraction was analyzed by SDS-PAGE, transferred to nitrocellulose, and probed with antibodies to sAnk1.
Blot overlay
The blot overlay assays were performed as previously described, with some modifications (Kontrogianni-Konstantopoulos et al., 2000) . In brief, aliquots (~2.5 µg) of bacterially expressed, affinity purified MBP and MBP-obscurin clone F proteins were separated 9 by 10% SDS-PAGE and transferred to nitrocellulose. Blots were first incubated in buffer A (50 mM Tris, pH 7.2, 120 mM NaCl, 3% BSA, 2 mM dithiothreitol, 0.5% plus protease inhibitors for 3 h at 25 0 C and then with 3 µg/ml GST or GST-sAnk1 polypeptides in buffer A for 16 h at 4 0 C. Blots were washed extensively with buffer A and once with buffer B (PBS pH 7.2, 10 mM NaN 3 , 0.1 % Tween-20). Subsequently they were blocked in buffer C (PBS, pH 7.2, 10 mM NaN 3, 0.1% Tween-20, 3% dry milk) and probed with antibodies to sAnk1 or GST.
Kinetic analysis of sAnk1 binding to obscurin with a surface plasmon resonance biosensor
Real-time evaluation of the kinetics of binding of sAnk1 to obscurin was performed with a BIACORE 3000 instrument (Biacore, Uppsala, Sweden). The association (k a , M -1 s -1 ) and (FC1 and FC2) of the activated CM5 chip through standard amine coupling, using the GST kit from Biacore.
Control GST-protein (~25 kDa), GST-sAnk1 (~39 kDa), GST-obscurin-F3 (~38.5 kDa), MBP-sAnk1 (~57 kDa) and MBP-obscurin-F3 (~66 kDa) were produced and affinity purified, as described above. Two sets of kinetics studies were performed. In the first, was immobilized on FC2, via its interaction with the immobilized GST-antibody, and MBP-sAnk1 was used as analyte. In the second, GST-sAnk1 was used as ligand and captured on FC2, and MBP-obscurin-F3 served as analyte. In both experiments, control GST-protein was bound to GST-antibody, immobilized on FC1, to correct for bulk effects and non-specific binding.
Each experimental set was repeated three times and yielded highly reproducible results.
All samples were diluted in freshly degassed, filter-sterilized HBS-EP buffer ( 
Preparation of soluble and insoluble muscle fractions
Quadriceps muscle from adult rats was homogenized as above in lysis buffer (10 mM NaPO 4 , pH 7.2, 120 mM NaCl, 2% Triton-100) in the presence of a cocktail of protease inhibitors (Roche), and incubated on ice for 1 h with occasional mixing. The homogenate was centrifuged at 14,000xg for 30 min at 4 0 C to yield a supernatant (the detergent soluble, or DS, fraction) and pellet. The pellet was dissolved in 2% SDS, 1% β-mercaptoethanol (β-ME), 120 mM NaCl, plus protease inhibitors, incubated on ice for 30 min with occasional mixing and spun at 14,000xg for 30 min at 4 0 C. The resultant supernatant was designated as the detergent insoluble (DI) fraction. Muscle was also homogenized in the presence of 10 mM NaPO 4 , pH 7.2, 2 mM EDTA, 10 mM NaN 3 , 120 mM NaCl, 1% NP-40, 0.5% deoxycholate plus protease inhibitors, incubated on ice for 1 h with occasional mixing, and spun, as above. antibodies to sAnk1 or obscurin, at a concentration of 100 ng/ml, in the same solution.
Immunoreactive bands were visualized with a chemiluminescence detection kit (Tropix, Bedford, MA).
Immunofluorescent labeling of adult skeletal and cardiac muscle
GST-obscurin clone B fusion protein was used to generate rabbit antibodies. Anti-serum was affinity purified over GST and GST-obscurin clone B columns to prepare antibodies specific for obscurin. Affinity-purified rabbit antibodies to sAnk1 have been described (Zhou et al., 1997) .
Frozen longitudinal and cross sections of adult rat myocardium and quadriceps muscle were prepared as described (Williams et al., 2001) . Sections were blocked with PBS containing 1 mg/ml BSA, 10 mM NaN 3, for 1-2 h at 25 0 C. Primary antibodies, including anti-obscurin (3 µg/ml), anti-sAnk1 (3 µg/ml), or ChromaPure rabbit IgG (3 µg/ml) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA), together with a monoclonal antibody to α-actinin (1:500; Sigma) were incubated with the sections for 12 h at 4 0 C. Samples were counterstained with either goat anti-rabbit-Alexa 568 or goat anti-rabbit-Alexa 568 and goat antimouse-Alexa 488 (Molecular Probes, Eugene, OR) at 1:100 dilution, for 1 h at 25 0 C. In immunodepletion experiments, anti-obscurin was pre-absorbed with 100 µg of GST-obscurin clone B antigen per ml of diluted, affinity-purified serum for 8-12 h at 4 0 C before labeling.
Sections were washed extensively with PBS, 1 mg/ml BSA, 10 mM NaN 3 , mounted with
Vectashield (Vector Laboratories, Burlingame, CA) and analyzed with a Zeiss 410 confocal laser scanning microscope (Carl Zeiss, Inc, Tarrytown, NY) equipped with a 63x, NA 1.4 objective.
Materials
Unless otherwise noted, all reagents were from Sigma Chemical Co. (St. Louis, MO) and were the highest grade available.
RESULTS
sAnk1 is an integral protein of the network SR, positioned with its COOH-terminal hydrophilic tail facing the myoplasm (Zhou et al., 1997; our unpublished results) . To identify potential binding partners of sAnk1 in skeletal muscle, we used its COOH-terminal tail aa29-155 as
"bait" to screen a cDNA library from adult rat skeletal muscle (Fig. 1A) . Approximately 5x10 6 transformants were screened, of which 12 "prey" clones met the stringent criteria for positive interactions. These were further characterized by DNA sequencing. Notably, 6 out of the 12 positive clones carried overlapping fragments of the COOH-terminal region of obscurin ( Fig.   1B ; Young et al., 2001) . No other "prey" sequence was present in more than one of the 12 clones examined.
The longest obscurin clone (A, ~2.7kb) contains a Rho-guanine nucleotide exchange factor (Rho-GEF) domain next to a pleckstrin homology (PH) region, followed by two immunoglobulin-like (Ig) domains and a long, non-modular COOH-terminus of 413 amino acids ( Fig. 2A) . The 3' end of the 6 obscurin "preys" all contained an in frame stop codon, followed by a 3'UTR of 525 bp that carries stop codons in all three reading frames (Fig. 2B ). Unlike the 3'UTR of human obscurin (Young et al., 2001) , the rat sequence contains a consensus polyadenylation signal upstream of the poly-A tail (Fig. 2B, underlined) . The smallest positive clone (F) encodes the most C-terminal 353 amino acids of obscurin as well as the 3'UTR, but it lacks the structural motifs present in the larger clone A. Thus, the sAnk1 binding site should lie within the COOH-terminal 353 amino acid residues of rat obscurin.
14 Comparison of the partial sequence of rat obscurin with its human orthologue (Young et al., 2001) showed extensive homology, especially within the signaling and structural domains.
In particular, the Rho-GEF, PH, and two Ig-like domains shared 98%, 95%, 94% and 80% identity, respectively ( Fig. 2A) . The COOH-terminal sequence showed lower identity (68%).
Overall, clone A was 83% similar and 77% identical to its human orthologue.
We used the yeast two-hybrid screen to identify the region of the cytoplasmic sequence of sAnk1 that binds obscurin, and to define more precisely the sequence of obscurin that binds sAnk1. For sAnk1, bait constructs encoding amino acids 29-89, 61-130 and 90-155 , were coexpressed in yeast with the prey vector encoding obscurin clone F (Fig. 3A) . Only sAnk1 aa61-130 elicited expression of β-galactosidase, suggesting that this 70 amino acid sequence, but not flanking regions of sAnk1, contains the binding site for obscurin. In a similar experiment, we expressed three fragments of obscurin clone F in the prey vector and assayed their ability to interact with the full cytoplasmic sequence of sAnk1, expressed in the bait vector. In this case, two fragments of obscurin clone F, encoding amino acid residues 447-596 and 501-621, equivalent to amino acid sequences 6258-6407 and 6312-6432 of human obscurin (Young et al., 2001 ), gave positive responses. Clone F1 aa447-596 gave only half the response of clone F3 aa501-621 and of full length clone F (Fig. 3B) , suggesting that it contains only part of the binding site for sAnk1. It therefore seems likely that the binding site on obscurin for sAnk1 is contained in clone F3 aa501-621 , equivalent to amino acids 6312-6432 of the human obscurin orthologue.
We performed a GST "pull down" assay to confirm that sAnk1 binds obscurin. For these experiments, we chose to use the original clones identified in the yeast two-hybrid screen, as they were more readily separated from GST alone. When we expressed obscurin clone F as a GST-fusion protein, the mass of the resultant polypeptide was only ~45 kDa, instead of the expected ~64 kDa (Fig. 4A, arrow) , probably due to endogenous bacterial proteases. The truncated band of ~45 kDa presumably contains GST (25 kDa) and the NH 2 -terminal ~20 kDa encoded by clone F (Fig. 4A, arrowhead) . The truncated, ~45 kDa GST-obscurin F fusion protein includes the entire sequence that we identified above as containing the minimal binding site for sAnk1 (Fig. 3B) . When skeletal muscle lysates were incubated with GST-obscurin clone F bound to glutathione matrix, native sAnk1 was efficiently and specifically adsorbed, as detected by Western blotting with antibodies to sAnk1 (Fig. 4B ). This interaction required obscurin clone F, as GST alone failed to adsorb sAnk1 (Fig. 4B) .
We also performed an overlay assay with sAnk1 aa29-155 and obscurin clone F, which were expressed in bacteria as GST-and MBP-fusion proteins (Fig. 4C) , respectively, to learn if sAnk1 binds obscurin directly. Equivalent amounts of MBP-obscurin clone F and MBP-protein were separated by SDS-PAGE, transferred to nitrocellulose, and incubated with GST-sAnk1 or GST- protein. Recombinant sAnk1 specifically bound to MBP-obscurin-F peptide, but not to MBPprotein, as shown by immunoblotting with antibodies to sAnk1 (Fig. 4D) . No specific binding was detected when an identical blot was overlaid with GST-protein and subsequently probed with antibodies to GST (Fig. 4E) . Furthermore, addition of a 20-fold excess of MBP-obscurin-F fusion protein to the overlay buffer significantly reduced binding of GST-sAnk1 (Fig. 4F) .
These results showed that sAnk1 and obscurin bind to each other directly.
We used a Biacore 3000 surface plasmon resonance biosensor (for review, see Myszka, 1997) to perform kinetic studies of the binding of sAnk1 to obscurin. Recombinant GSTsAnk1 aa29-155 (~39 kDa), MBP-sAnk1 aa29-155 (~57 kDa), GST-obscurin-F3 aa501-621 (~38.5 kDa) and MBP-obscurin-F3 aa501-621 (~66 kDa) were generated (Fig. 5A ). Two sets of kinetic studies were performed. In the first, GST-obscurin-F3 was used as ligand, with GST alone as control (see Materials and Methods). Different concentrations of MBP-sAnk1, ranging from 0-300 nM, were flowed over immobilized GST-obscurin-F3 and GST. Real time binding of MBP-sAnk1 to GST-obscurin-F3 was evaluated after subtraction of non-specific binding to control GST. The sensograms for the different analyte concentrations were overlaid and aligned to the baseline, established in the absence of MBP-sAnk1 (Fig. 5B ). An increasing amount of MBP-sAnk1 bound to GST-obscurin-F3 during the injection period (3 min), and binding reversed relatively slowly during the dissociation phase (3 min). The sensogram data were quantified by performing kinetics analysis using BIAevaluation 3.1 software and fitted with the 1:1 Langmuir binding model. Three independent kinetic experiments were performed that yielded similar results ( Table I ). The kinetic constants for the "on" (ka) and "off" (kd) reactions were 1.42x10 4 M -1 s -1 and 1.79x10 -3 s -1 respectively. An average binding affinity, K D, of 130 nM was determined.
Chi 2 values calculated for these experiments were very low, suggesting that these values provided an excellent fit to the data.
We performed a similar set of kinetic studies using GST- (Table I) . Although we obtained a better fit of these data with the Heterogeneous Ligand model, consistent with the presence of two subpopulations of recombinant GST-sAnk1 in our fusion protein preparation (Fig. 5A, lane 1) , the low chi 2 value obtained with the 1:1 Langmuir analysis suggests that most of the GST-sAnk1 remains intact and active during the biosensor assay. Thus, these studies collectively demonstrated a dissociation equilibrium constant (K D ) for the binding of sAnk1 to obscurin in the middle nM range.
We used the GST-obscurin clone B fusion protein as an antigen to generate polyclonal antibodies in rabbits. Specific antibodies were affinity purified and used to characterize obscurin in muscle homogenates. Quadriceps skeletal muscle was homogenized with non-denaturing detergents and the soluble and insoluble material was analyzed by SDS-PAGE and immunoblotting. Small amounts of obscurin were present in the detergent soluble (DS) fraction, but an ~800 kDa immunoreactive band was readily and specifically detected in the detergent insoluble (DI) pellet (Fig. 6A ). Unlike obscurin, sAnk1 was enriched in the DS fraction, with only trace amounts in the DI fraction (Fig. 6B) . These results are consistent with a sarcomeric location for obscurin as well as with the known concentration of sAnk1 in the network SR (Zhou et al., 1997) .
The insolubility of obscurin in muscle homogenates made studies of its association with sAnk1 in solution difficult. We therefore used immunofluorescence combined with confocal microscopy to compare the subcellular distributions of obscurin and sAnk1. Frozen sections of adult quadriceps were labeled with antibodies to obscurin together with antibodies to α-actinin, to mark Z-lines. Obscurin was present in striations in register with Z-lines, as well as midway in between, at M-lines (Fig. 7A-C) . In cross sections, obscurin assumed a reticular distribution (Fig. 7D ). Both patterns were identical to those earlier reported for sAnk1 (Zhou et al., 1997) .
We also examined the subcellular localization of obscurin and sAnk1 in adult myocardium. In ventricular muscle, both obscurin and sAnk1 are primarily at M-lines and to a lesser extent at Z-disks ( Fig. 7E-F ). These observations are consistent with the distribution of the network SR in cardiac muscle, which, unlike skeletal muscle, is more prevalent at the level of the M-line. No labeling was detected when primary antibodies were either replaced by nonimmune rabbit IgG (Fig. 7G) or pre-adsorbed with their respective antigens (Fig. 7H ).
DISCUSSION
As part of an effort to understand how the SR becomes aligned with the myofibrils of striated muscle, we used the yeast two-hybrid screen to identify ligands of sAnk1. sAnk1 is enriched in the network SR, to which it is anchored by its NH 2 -terminal, hydrophobic head (Zhou et al., 1997; our unpublished studies) . Its COOH-terminal sequence extends into the cytoplasm, where it may interact with other proteins. Here we show that the major ligand of the cytoplasmic domain of sAnk1 is the COOH-terminal region of obscurin, a giant protein of striated muscle that concentrates at the level of the Z-disks and M-lines (Young et al., 2001) . They are also unique in other respects, as they demonstrate previously unknown properties of both the ankyrin and the titin superfamilies of proteins.
The C-terminal portion of the large, canonical forms of ankyrin (see Introduction) has been referred to as the "regulatory domain" of the protein, because its phosphorylation alters the affinity of the spectrin-and membrane-binding domains of ankyrin for their respective ligands (Bennett, 1992) . Although it is clear that this region must bind at least transiently to kinases and 20 phosphatases, a ligand for the C-terminal sequence of ankyrin has not yet been identified. Here we show that the C-terminal region of sAnk1, between amino acids 61 and 130, has binding activity for obscurin. This binding site contains sequence that is shared with the C-terminal region of the large, canonical ankyrin 1 (sAnk1 aa74-130 ), as well as sequence that is unique to sAnk1
(sAnk1 aa61-73 ). It remains to be determined if the binding of sAnk1 to obscurin is mediated by the sequence shared with the large canonical ankyrin 1 or by the unique sequence, or if both must be present to form the binding site.
Obscurin resembles two other giant proteins of striated muscle, titin and nebulin (Wang, 1996; Gregorio et al., 1999) . Like those proteins, obscurin contains multiple Ig domains and it is tightly associated with the contractile apparatus, as indicated by its limited solubility in nondenaturing detergents (Isaacs et al., 1989; Granzier and Wang, 1993) . It therefore seems probable that, like titin and nebulin, obscurin binds to one or more proteins of the contractile apparatus with high affinity. Consistent with this, obscurin binds titin, though in a region of that protein that does not precisely coincide with the Z-disk or M-line (Young et al., 2001 ). In addition to its ability to bind titin, our results clearly show that obscurin also binds sAnk1. It is the first member of the titin superfamily to be shown to bind to an integral membrane protein.
The antibodies to obscurin that we have generated to date are to its C-terminal, sAnk1-binding region. This raises some questions about the isoforms of obscurin we have studied, and also about its possible location and orientation in the sarcomere. The C-terminal sequence is present in the ~800 kDa product of the obscurin gene and in some of its smaller, alternatively spliced products, but not in those products that contain COOH-terminal ser/thr kinase domains (Russel et al., 2002) . Although our antibodies recognize some smaller proteins in adult skeletal 21 muscle (our unpublished observations), most of the obscurin we detect is ~800 kDa. Thus, obscurin at Z-disks and M-lines is likely to be ~800 kDa in mass.
As this giant form of obscurin is predicted to be 208 nm in length (Young et al., 2001) , its positioning within the sarcomere may be difficult to determine from immunolabeling with antibodies to its C-terminus alone. For example, obscurin also may be present in the interior of the sarcomere, where its COOH-terminal epitopes could be inaccessible. Alternatively, obscurin may be concentrated at many points along the surface of the sarcomere in a longitudinal orientation, with its COOH-terminal region exposed and accessible to antibodies only at the peripheries of the Z-disk and M-line. Finally, obscurin may be completely restricted to the Zdisk and M-line, either with its NH 2 -terminal region buried in the interior of those structures and its COOH-terminal sequence exposed at the surface and accessible to sAnk1, or with both NH 2 -and COOH-terminal regions at the periphery. The latter possibility, which is consistent with results from other laboratories that used antibodies to more N-terminal epitopes to label obscurin at Z-lines and M-lines (Young et al., 2001; Bang et al., 2001) , suggests that obscurin surrounds the myofibril at the ends and in the middle of each sarcomere.
If this is correct, obscurin also differs from titin and nebulin in its positioning with respect to the contractile apparatus. Titin and nebulin are both found in the interior of the sarcomere, where they extend longitudinally, from the Z-disk to the M-line and along the thin filaments, respectively (Trombitas et al., 2000; Ojima et al., 2000) . Titin and nebulin play important roles in determining the longitudinal dimensions of these sarcomeric elements (Nwe et al., 1999; Nwe and Shimada, 2000; McElhinny et al., 2001; Sutco et al., 2001; Granzier and Labeit, 2002; Watanabe et al., 2002) , but a similar "molecular ruler" to determine the diameter of 22 the sarcomere has not yet been identified. As the first member of the titin superfamily to associate with the sarcomere only at its periphery, obscurin may serve this function.
Our results demonstrate that sAnk1, a protein of the SR, binds to obscurin, a protein that associates preferentially with the contractile apparatus of striated muscle. This binding interaction is probably limited to muscle, however. Although sAnk1 is also expressed in the brain (White et al., 1992) , the 800 kDa form of obscurin is expressed only in skeletal and cardiac tissue (Young et al., 2001) and so is unlikely to be involved in linking the endoplasmic reticulum (ER) to the cytoskeleton in other cells. Studies from several in vitro systems have documented that the cytoskeleton contributes to dynamic changes in the ER but is not necessary for its organization or maintenance (Bauman and Walz, 2001, Voeltz et al, 2002) . Indeed, the ER in non-muscle cells appears to be only weakly anchored to the cytoskeleton, as it continuously changes its shape and subcellular location (Koch and Booth, 1988 , Yang et al., 1997 , Voeltz et al., 2002 .
The links between the SR and the contractile apparatus in muscle cells are likely to be much firmer than the links between the ER and the cytoskeleton in non-muscle cells, because the orientation of the SR with respect to the contractile elements is invariant in each type of striated fiber. Our results suggest that the binding of sAnk1 to obscurin in vivo is in part responsible for this orientation (Fig. 8) . For example, the C-terminal region of obscurin is sited appropriately to bind to sAnk1 in the network SR. Similarly, sAnk1 is located and oriented in the SR membrane to permit its C-terminal domain to interact with obscurin. These two molecules bind to each other with high affinity and are enriched in the same regions of skeletal and cardiac muscle.
Given their close association, we propose that the binding of sAnk1 to obscurin contributes to the 23 regular alignment of the network SR with the Z-disks and M-lines of striated muscle.
Experiments to test this model are now in progress. 
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